{"schema_version":"secwatch.filing_event.v1","accession":"0001636282-24-000105","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2024-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.058112+00:00","generated_at":"2026-05-29T23:04:02.340991+00:00","sec_items":["4.02","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Spyre Therapeutics restates net loss per share from 2023-2024; material weakness in controls","bullets":["Restating audited and unaudited financials from Dec 31, 2023 to Sep 30, 2024 due to misapplication of GAAP in EPS calculation for preferred stock.","Common stock net loss per share changed for all affected periods; e.g., Q3 2024 revised from ($1.36) to ($1.06).","Series A Preferred stock EPS restated (e.g., Q3 2024: ($42.22) vs. not previously reported).","Material weakness in internal controls over financial reporting identified; remediation plan to be filed.","No impact on cash position or other financial data; amendments to prior filings expected soon."],"urls":{"canonical":"https://secwatch.observer/filing/0001636282-24-000105","json":"https://secwatch.observer/filing/0001636282-24-000105.json","markdown":"https://secwatch.observer/filing/0001636282-24-000105.md","text":"https://secwatch.observer/filing/0001636282-24-000105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000163628224000105/0001636282-24-000105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000163628224000105/syre-20241118.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T23:04:02.340991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001750155-26-000080","ticker":"CWBHF","company_name":"Charlotte's Web Holdings, Inc.","filed_at":"2026-06-01T21:13:23+00:00","headline":"Charlotte's Web appoints BAT GC to board, closes debt conversion & US$10M investment","event_type":"other_material","sec_items":["5.02","5.07","8.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001750155-26-000080","json":"https://secwatch.observer/filing/0001750155-26-000080.json","markdown":"https://secwatch.observer/filing/0001750155-26-000080.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750155/000175015526000080/0001750155-26-000080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750155/000175015526000080/cweb-20260528.htm"},"side_by_side_evidence":null},{"accession":"0001790340-26-000059","ticker":"IMRX","company_name":"Immuneering Corp","filed_at":"2026-06-01T20:51:53+00:00","headline":"Immuneering reports 17.3-month median OS in Phase 2a pancreatic trial of atebimetinib","event_type":"other_material","sec_items":["8.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-26-000059","json":"https://secwatch.observer/filing/0001790340-26-000059.json","markdown":"https://secwatch.observer/filing/0001790340-26-000059.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000059/0001790340-26-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000059/imrx-20260601.htm"},"side_by_side_evidence":null},{"accession":"0000798359-26-000057","ticker":"CSR","company_name":"CENTERSPACE","filed_at":"2026-06-01T20:30:13+00:00","headline":"Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000798359-26-000057","json":"https://secwatch.observer/filing/0000798359-26-000057.json","markdown":"https://secwatch.observer/filing/0000798359-26-000057.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/798359/000079835926000057/0000798359-26-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/798359/000079835926000057/iret-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001689548-26-000053","ticker":"PRAX","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2026-06-01T20:28:49+00:00","headline":"Praxis Precision Medicines: Phase 2/3 vormatrigine study fails primary endpoint in focal seizures","event_type":"other_material","sec_items":["8.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-26-000053","json":"https://secwatch.observer/filing/0001689548-26-000053.json","markdown":"https://secwatch.observer/filing/0001689548-26-000053.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000053/0001689548-26-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000053/prax-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001185185-26-002273","ticker":"DGAC","company_name":"DISCIPLINED GROWTH ACQUISITION Corp","filed_at":"2026-06-01T20:15:34+00:00","headline":"Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002273","json":"https://secwatch.observer/filing/0001185185-26-002273.json","markdown":"https://secwatch.observer/filing/0001185185-26-002273.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/dgac8k052926.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063500","ticker":"PLUR","company_name":"Pluri Inc.","filed_at":"2026-06-01T20:06:43+00:00","headline":"Pluri gets EIB nod for loan talks; no enforcement until July 3 on €20M maturing today","event_type":"other_material","sec_items":["8.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063500","json":"https://secwatch.observer/filing/0001213900-26-063500.json","markdown":"https://secwatch.observer/filing/0001213900-26-063500.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1158780/000121390026063500/0001213900-26-063500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1158780/000121390026063500/ea0292940-8k_pluri.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251399","ticker":"IDYA","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2026-06-01T20:05:32+00:00","headline":"IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251399","json":"https://secwatch.observer/filing/0001193125-26-251399.json","markdown":"https://secwatch.observer/filing/0001193125-26-251399.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/0001193125-26-251399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/d138848d8k.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251394","ticker":"FULC","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2026-06-01T20:05:16+00:00","headline":"Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251394","json":"https://secwatch.observer/filing/0001193125-26-251394.json","markdown":"https://secwatch.observer/filing/0001193125-26-251394.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526251394/0001193125-26-251394-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526251394/fulc-20260601.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}